Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma

Author(s): Arzu D. Yalcin*, Rusen Uzun.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 35 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Multi-center, randomized-controlled trials and observational studies have demonstrated that, in severe asthmatic patients receiving omalizumab treatment, the frequency of exacerbations, the number of urgent adverse events, and the need for oral steroids tend to decrease.

Materials and Methods: This study included a total of 32 patients. The patients were divided into two groups as Group IA (pre-omalizumab) and Group IB (post-omalizumab). Serum IL-25 and IL-33 levels were measured and the number of emergency admissions, length of hospitalization (day), Asthma Control Test (ACT) scores, eosinophil cationic protein (ECP), and fractional exhaled nitric oxide (FeNO) value were analyzed.

Results: ACT and FeNO values increased after omalizumab treatment, while IL-33, IL-25 levels decreased after the completion of omalizumab treatment. Furthermore, there was a weak, positive, and significant relationship between the changes in the ECP levels and IL-33 levels (r=0.38, p=0.03).

Conclusion: To the best of our knowledge, this is the first study to compare circulating IL-25 and IL-33 levels with specific IgE synthesis in the literature. Multivariate correlation analysis showed that the changes in serum IL-33 levels were significantly correlated with the changes in the mite sIgE levels and length of hospital stay (Fmodel=11.2, p=0.01, r2=0.45). On the other hand, there was no significant relationship between the other variables and changes in the IL-25 levels.

Keywords: IL25, IL-33, ECP, Omalizumab, severe persistent asthma (SPA), Anti-IgE, spesific IgE, vitamin-D.

[1]
Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at: http://www.ginasthma.org/guidelinesgina-report-globalstrategy-for-asthma.html2018
[2]
Yalcin AD, Bisgin A, Cetinkaya R, Yildirim M, Gorczynski RM. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. Clin Lab 2013; 59(1-2): 71-7.
[http://dx.doi.org/10.7754/Clin.Lab.2012.120406] [PMID: 23505909]
[3]
Yalcin AD. Advances in anti-IgE therapy. BioMed Res Int 2015; 2015317465
[http://dx.doi.org/10.1155/2015/317465] [PMID: 26075226]
[4]
DuBuske LM. IgE, allergic diseases, and omalizumab. Curr Pharm Des 2006; 12(30): 3929-44.
[http://dx.doi.org/10.2174/138161206778559641] [PMID: 17073688]
[5]
Yorgancıoğlu A, Öner Erkekol F, Mungan D, et al. Long-term omalizumab treatment: a multicenter, real-life, 5-year trial. Int Arch Allergy Immunol 2018; 176(3-4): 225-33.
[http://dx.doi.org/10.1159/000488349] [PMID: 29772578]
[6]
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139(1): 28-35.
[http://dx.doi.org/10.1378/chest.10-1194] [PMID: 20688929]
[7]
Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013; 17(52): 1-342.
[http://dx.doi.org/10.3310/hta17520] [PMID: 24267198]
[8]
Kawamatawong T, Poachanukoon O, Boonsiri C, et al. Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience. Asian Pac J Allergy Immunol 2018; 36(4): 238-43.
[http://dx.doi.org/10.12932/AP0872] [PMID: 29161053]
[9]
Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012; 6(4): 215-27.
[http://dx.doi.org/10.1111/j.1752-699X.2011.00263.x] [PMID: 21740532]
[10]
Korn S. Thielena, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a reallife setting in Germany. Respir Med 2009; 103(11): 1725-31.
[http://dx.doi.org/10.1016/j.rmed.2009.05.002] [PMID: 19515548]
[11]
Storms W, Bowdish MS, Farrar JR. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. Allergy Asthma Proc 2012; 33(2): 172-7.
[http://dx.doi.org/10.2500/aap.2012.33.3527] [PMID: 22525394]
[12]
Tural Onur S, Yalcin AD, Celik B, Gumuslu S. Evaluation of d-dimer, CXCL8, homocysteine, eosinophil cationic peptide, 25(OH)-vitamin D and immunomodulatory OX-2 levels in allergic patients. J Asthma 2015; 52(2): 123-7.
[http://dx.doi.org/10.3109/02770903.2014.936450] [PMID: 24986253]
[13]
Yalcin AD, Cilli A, Bisgin A, Strauss LG, Herth F. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opin Biol Ther 2013; 13(9): 1335-41.
[http://dx.doi.org/10.1517/14712598.2013.819338] [PMID: 23883435]
[14]
Yalcin AD, Uçar S, Gumuslu S, Strauss LG. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter’s syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013; 35(4): 524-7.
[http://dx.doi.org/10.3109/08923973.2013.811598] [PMID: 23841472]
[15]
Watanabe Y, Tajiki-Nishino R, Tajima H, Fukuyama T. Role of estrogen receptors α and β in the development of allergic airway inflammation in mice: a possible involvement of interleukin 33 and eosinophils. Toxicology 2019; 411: 93-100.
[http://dx.doi.org/10.1016/j.tox.2018.11.002] [PMID: 30445053]
[16]
Yao X, Sun Y, Wang W, Sun Y. Interleukin (IL)-25: pleiotropic roles in asthma. Respirology 2016; 21(4): 638-47.
[http://dx.doi.org/10.1111/resp.12707] [PMID: 26699081]
[17]
Jayapal M, Tay HK, Reghunathan R, et al. Genome-wide gene expression profiling of human mast cells stimulated by IgE or FcepsilonRI-aggregation reveals a complex network of genes involved in inflammatory responses. BMC Genomics 2006; 7: 210.
[http://dx.doi.org/10.1186/1471-2164-7-210] [PMID: 16911805]
[18]
Li Y, Chen S, Chi Y, et al. Kinetics of the accumulation of group 2 innate lymphoid cells in IL-33-induced and IL-25-induced murine models of asthma: a potential role for the chemokine CXCL16. Cell Mol Immunol 2019; 16(1): 75-86.
[http://dx.doi.org/10.1038/s41423-018-0182-0] [PMID: 30467418]
[19]
Fournié JJ, Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity: a yin and yang cytokine. Front Immunol 2018; 9: 2506.
[http://dx.doi.org/10.3389/fimmu.2018.02506] [PMID: 30416507]
[20]
Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012; 2012720976
[http://dx.doi.org/10.1155/2012/720976] [PMID: 23316107]
[21]
Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the Asthma-COPD Overlap Syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol 2016; 38(3): 253-6.
[22]
Yalcin AD, Bulut T, Celik B, Genc GE, Gocmen AY, Gumuslu S. Are thermogenic proteins and adipokine chemerin affected by monoclonal antibody therapy in asthma?. Eurasian J Pulmonol
[http://dx.doi.org/104103/ejopejop_60_18]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 35
Year: 2019
Page: [3784 - 3795]
Pages: 12
DOI: 10.2174/1381612825666190930095725
Price: $65

Article Metrics

PDF: 19
HTML: 8